
SFA Therapeutics
SFA Therapeutics is a YC Summer 2021 (S21) company. Based in Philadelphia, PA, USA. Team of 4.
About SFA Therapeutics
Summary
SFA Therapeutics develops oral small-molecule drugs that regulate the immune system by targeting the gut-immune axis, with the goal of treating autoimmune diseases and cancers driven by chronic inflammation. Its lead candidate, SFA-002, is an oral deuterated short-chain fatty acid in clinical development for plaque psoriasis, with Phase 1b data in hand and human data across pancreatic cancer, uveitis, and NASH. The pipeline replaces biologics and immunosuppressants with a clean-profile oral therapy aimed at the root inflammatory mechanisms shared across more than 300 million patients worldwide.
From the Y Combinator listing
Regulating the immune system to block cancer & autoimmune diseases
SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.
Facts
- Healthcare / Healthcare -> Therapeutics
- Philadelphia, PA, USA
- 4
- Active
- Early
Founders (3)
- Alla Arzumanyan
- Ira Spector
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works